Santhera Pharmaceuticals Holding (SANN) AI Stock Analysis

• Market Cap: $140.58M
• Dividend Yield: N/A
• Average Volume (3M): 95.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -56.85%
• EPS Growth: -186.55%
• Country: CH
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.04
• Shares Outstanding: 14,010,270
• 10 Day Avg. Volume: 100,934
• 30 Day Avg. Volume: 95,230
• PEG Ratio: 0.02
• Price to Book (P/B): 5.68
• Price to Sales (P/S): 4.02
• P/FCF Ratio: -4.41
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: 4.30
• Enterprise Value/Gross Profit: 35.80
• Enterprise Value/Ebitda: -6.48
• 1Y Price Target: $30.32
• Price Target Upside: 182.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: CHF10.00 ▼(-6.89% Downside)

Santhera Pharmaceuticals' overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The positive sentiment from the earnings call provides some optimism, but the company's high leverage and ongoing losses weigh heavily on its valuation.

Positive Factors

Market Expansion

The expansion into new markets like the U.K. and Europe enhances Santhera's market reach and potential revenue streams, supporting long-term growth.

Product Adoption

Strong adoption of AGAMREE in key markets indicates robust demand and competitive positioning, which can drive sustained revenue growth.

Revenue Guidance

Increased revenue guidance reflects confidence in market performance and product demand, suggesting potential for improved financial results.

Negative Factors

High Leverage

High leverage indicates reliance on debt financing, which can strain financial flexibility and increase risk during economic downturns.

Operating Loss

Significant operating losses highlight ongoing profitability challenges, which may impact long-term financial sustainability if not addressed.

Cash Flow Challenges

Negative cash flow from operations suggests difficulties in self-financing, necessitating reliance on external funding, which could hinder growth.

Santhera Pharmaceuticals Holding Business Overview & Revenue Model

Company Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

How the Company Makes Money

Santhera Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products. Key revenue streams include sales of approved drugs, potential royalties from partnered products, and milestone payments from collaborations with other pharmaceutical companies. The company actively seeks partnerships to expand its market reach and enhance its product pipeline. Additionally, Santhera may receive funding through grants and subsidies aimed at supporting research and development in rare diseases, which contribute to its financial sustainability.

Santhera Pharmaceuticals Holding Financial Statement Overview

Summary

Santhera Pharmaceuticals faces significant financial challenges, including volatile revenue, negative profitability, high leverage, and cash flow difficulties. Despite a strong revenue year in 2023, the company needs operational improvements and financial restructuring for stability.

Income Statement

Santhera Pharmaceuticals has shown a volatile revenue trend with a significant drop in 2024 compared to 2023. The company struggles with profitability as indicated by negative EBIT and net income margins. However, past revenue growth was notable in 2023, suggesting potential for recovery if operational issues are addressed.

Balance Sheet

The company's balance sheet shows high leverage with a debt-to-equity ratio exceeding 1, indicating reliance on debt financing. The equity ratio is low, reflecting weak equity position. Persistent negative stockholders' equity in some years raises concerns about financial stability.

Cash Flow

Cash flow from operations has been negative in recent years, indicating challenges in generating cash internally. Positive financing cash flows highlight reliance on external funding. Free cash flow turned negative, suggesting cash management issues despite periods of positive operating cash flow in the past.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.02M	39.12M	103.41M	7.47M	-1.59M	15.01M
Gross Profit	5.89M	22.96M	100.18M	3.88M	-5.36M	4.58M
EBITDA	-32.52M	-15.89M	79.17M	-46.78M	-34.57M	-53.43M
Net Income	-65.54M	-41.97M	54.78M	-71.08M	-55.53M	-67.66M
Balance Sheet
Total Assets	130.77M	152.49M	109.63M	63.73M	91.12M	88.69M
Cash, Cash Equivalents and Short-Term Investments	18.40M	40.92M	30.37M	1.35M	21.21M	12.41M
Total Debt	76.30M	41.17M	23.03M	44.44M	42.98M	71.17M
Total Liabilities	133.33M	124.79M	49.69M	107.41M	89.79M	95.04M
Stockholders Equity	-2.56M	27.70M	59.94M	-43.69M	1.33M	-6.35M
Cash Flow
Free Cash Flow	-40.92M	-35.68M	23.53M	-33.80M	-37.37M	-43.54M
Operating Cash Flow	-40.84M	-35.53M	47.27M	-29.84M	-37.36M	-43.51M
Investing Cash Flow	-142.00K	-61.00K	-18.04M	-3.93M	69.00K	1.56M
Financing Cash Flow	44.82M	46.08M	-171.00K	13.99M	46.02M	23.15M

Santhera Pharmaceuticals Holding Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SANN, the sentiment is Neutral. The current price of 10.74 is above the 20-day moving average (MA) of 10.33, below the 50-day MA of 11.43, and below the 200-day MA of 13.39, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 52.38 is Neutral, neither overbought nor oversold. The STOCH value of 57.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:SANN.

Santhera Pharmaceuticals Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	74 Outperform	$285.44M	11.94	―	―	744.64%	―
BSLN	73 Outperform	CHF568.22M	7.80	―	―	58.51%	―
MOLN	55 Neutral	$129.20M	-1.97	-49.86%	―	-100.00%	14.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDIA	45 Neutral	CHF790.83M	-4.75	―	―	228.54%	63.37%
SANN	41 Neutral	$140.58M	-2.05	-301.13%	―	-56.85%	-186.55%

Santhera Pharmaceuticals Holding Corporate Events

Santhera’s Earnings Call: Positive Outlook Amid Challenges

Santhera Pharmaceuticals Holding AG’s recent earnings call conveyed a generally positive sentiment, underscored by the robust market adoption of AGAMREE in Europe and the U.S., alongside a successful commercial rollout in China. Despite these achievements, the company also faced challenges, including a significant operating loss and the necessity for additional financing.

Santhera Pharmaceuticals Reports Strong H1 2025 Growth

Santhera Pharmaceuticals Holding AG, a Swiss specialty pharmaceutical company, focuses on developing and commercializing treatments for neuromuscular and pulmonary diseases, with a particular emphasis on rare conditions with high unmet needs. In its half-year 2025 financial report, Santhera highlighted a significant 70% increase in total revenue, reaching CHF 24 million, driven by the strong performance of AGAMREE® for Duchenne muscular dystrophy. The company also reported a 76% rise in product sales, primarily from Germany, Austria, and the UK, and a substantial increase in royalties from licensing partners in the U.S. and China.